Clinical trials: Venous Thromboembolic Event
Venous Thromboembolic Disease
Value of D-dimer Combined With Other Thrombus Molecular Markers in Risk Assessment of VTE in Hospitalized Patients
The occurrence of VTE in hospital is an important cause of unexpected death of inpatients, and has become a serious problem faced by hospital managers and clinical medical staff.Under the target of "Improving the Standard…
- Trial name
- NCT05515549
- Testing
- Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
Traumatic Brain Injury
PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).
- Trial name
- PROTEST (NCT03559114)
- Testing
- Dalteparin, Saline
- Where
- 12 sites in Canada
- Volunteers
- 1,100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Atrial Fibrillation, Venous Thromboembolism
START-Register: Survey on Anticoagulated Patients Register
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs).
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- NCT02219984
- Testing
- Anticoagulants
- Where
- Italy
- Volunteers
- 15,410 people
- Sponsor
- GUALTIERO PALARETI
Arthroplasty, Replacement, Thromboembolism
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
An observational cohort study on safety and efficacy of the 220 mg dose Pradaxa to generate additional data in predefined sub populations of patients at increased risk of bleeding or VTE
- Trial name
- NCT00846807
- Where
- 112 sites in Austria, France and 7 more
- Volunteers
- 5,476 people
- Sponsor
- Boehringer Ingelheim
COVID-19 Disease, Thromboembolism, Venous
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an…
- Trial name
- VTE-COVID (NCT04359212)
- Testing
- thromboprophylaxis with low-molecular-weight heparin or fondaparinux
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Quovadis Associazione
Arthroplasty, Replacement, Knee
Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects
This First-In-Human study will evaluate the safety and tolerability, pharmacokinetic profile, and pharmacodynamic effects of EP-7041, a novel Factor XIa inhibitor, following IV administration of single ascending doses in healthy…
- Trial name
- NCT02914353
- Testing
- EP=7041
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- eXIthera Pharmaceuticals
Thrombosis, Venous, Bleeding Hemorrhage
Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer, after disease progression. VTE is increasingly recognized as a complication in patients with hematologic malignancies and various studies…
- Conditions
- Thrombosis, Venous, Bleeding Hemorrhage, Venous Thromboembolic Disease, Hematologic Malignancy
- Trial name
- NCT05396157
- Where
- Canada
- Volunteers
- 813 people
- Sponsor
- Mount Sinai Hospital, Canada
Liver Cirrhosis
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).
- Trial name
- NCT04874428
- Testing
- Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Postpartum, VTE Prophylaxis
Excretion of Rivaroxaban in Human Breast Milk
The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.
- Conditions
- Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban
- Trial name
- LACT (NCT06831474)
- Testing
- Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Cervical Cancer, Endometrial Cancer
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00381888
- Testing
- fondaparinux sodium
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pulmonary Embolism
Pulmonary Embolism Registry
Acute Pulmonary Embolism (PE) is the most serious clinical presentation of venous thromboembolism (VTE), a leading cause of cardiovascular mortality, exceeded only by stroke and myocardial infarction.
- Trial name
- PER (NCT05391646)
- Volunteers
- 500 people
- Sponsor
- Universidade do Porto
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Venous Thromboembolism, Pulmonary Embolism
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional…
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer
- Trial name
- NCT06451003
- Testing
- Exposure to clinical decision support system and education
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events.
- Trial name
- NCT06619483
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Heparin-induced Thrombocytopenia
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Heparin is an anticoagulant (blood thinner) that is commonly used to treat patients with heart attacks and patients with blood clots in their legs or lungs (venous thrombosis).
- Trial name
- NCT01598168
- Testing
- Rivaroxaban
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McMaster University
Venous Thromboembolism, Pulmonary Embolism
Epidemiology of Venous Thromboembolism
More than 5 years ago the DVT FREE Registry was conceived. Its database consists of 5,451 ultrasound-confirmed DVT patients from 183 institutions.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis
- Trial name
- NCT00456196
- Where
- United States
- Volunteers
- 5,451 people
- Sponsor
- Brigham and Women's Hospital
Thromboembolism
Venous Thromboembolism (VTE) Knowledge
Venous thromboembolism (VTE) is common especially among post-operative patients, and its occurrence is associated with significant morbidity and mortality.
- Trial name
- NCT05548010
- Testing
- No intervention as this is an observational study
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Cerebral Venous Sinus Thrombosis
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were…
- Trial name
- NCT06551402
- Testing
- Dabigatran Etexilate 150mg, Rivaroxaban 20 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Medical Patients, Renal Insufficiency
Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
Fondaparinux is a parenteral anticoagulant drug and is approved for the prevention of venous thromboembolism in high risk medical patients.
- Trial name
- NCT00927602
- Testing
- fondaparinux
- Where
- Italy
- Volunteers
- 206 people
- Sponsor
- Università degli Studi dell'Insubria
Venous Thrombosis, Pulmonary Embolism
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Blood clots in the leg veins, known as deep vein thrombosis, are important because they may travel to the lung (known as pulmonary embolism) and cause death. Blood clots are treated with blood thinners, or anticoagulants.
- Trial name
- NCT00186745
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- St. Joseph's Healthcare Hamilton